
News|Videos|February 10, 2021
Pandemic Response Lessons
Author(s)Pharmaceutical Technology Editors
Lessons learned from the pandemic can advance future biologic drug development and manufacturing.
Advertisement
How have biopharma companies responded and adjusted to pandemic issues? What lessons learned under fire may lead to more effective and efficient bioprocessing practices going forward? Eric Langer, managing partner, BioPlan Associates, Inc., shared research and expert insight in Delivering on the Promise: Overcoming Biopharma Development and Manufacturing Challenges.
This presentation and Q&A with BioPharm International editors was recorded during the 2020 Bio/Pharma Virtual Congress on Nov. 11, 2020.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
PharmTech Weekly Roundup—August 14, 2026
2
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
3
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
4
Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?
5




